Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation (CTOT-16)

Trial Profile

Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation (CTOT-16)

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Basiliximab; Methylprednisolone; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CTOT16
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 May 2017 Results assessing pre-transplant panel reactive T Cells (PRT) with IL-15 as a risk-stratifier of acute rejection in Kidney Transplant patients, presented at the 2017 American Transplant Congress
    • 16 Sep 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top